TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04293328

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: orthokeratology
Description: Nightly wear of orthokeratology lenses to correct vision in the daytime

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: orthokeratology
Description: Nightly wear of orthokeratology lenses to correct vision in the daytime

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Menicon Progent A+B
Description: Menicon Progent A+B is a commercially available protein remover for rigid lenses. It has received FDA clearance and been launched in Hong Kong for over a decade. The product contains two separate sterile solutions, one with sodium hypochlorite and the other with potassium bromide. By mixing the two solutions in a special vial, it can clean and remove protein deposits on the lenses. Parents of subjects assigned to use weekly protein remover will be required to soak the cleansed lenses in the solution mixture for not more than 30 mins every week. All lenses must be rinsed thoroughly with saline and cleansed with daily cleaner again before daily disinfection.
Study: NCT03596892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine was administered at 20mg/m2/day on days -14 and -10.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study: NCT01551108

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention: limited behavioral strategies
Description: Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents are also sent monthly healthy nutrition tips via text message targeting the child in order to provide these families with potentially health promoting information.
Study: NCT01283178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography/computed tomography
Description: Undergo FDG/FLT-PET scans for IMRT/IGARTT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Undergo FDG-PET scans for IMRT/IGART
Study: NCT03480646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-1205
Description: Administered orally
Study: NCT02367183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301
Study: NCT03480646

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPI-1205
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone/Prednisone
Description: Administered orally
Study: NCT03803449

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 50-200mg propofol
Description: participants in both groups are given standard regimen including 50-200mg propofol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50-200mg propofol
Description: participants in both groups are given standard regimen including 50-200mg propofol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50ug fentanyl
Description: participants in fentanyl group are given intervention regimen: 50ug fentanyl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1 mg midazolam
Description: participants in both groups are given standard regimen including 1 mg midazolam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg midazolam
Description: participants in both groups are given standard regimen including 1 mg midazolam.
Study: NCT02789189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nedaplatin and gemcitabine
Study: NCT02776306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Box therapy
Description: In mirror box therapy the patient uses the reflection of their good arm to trick to brain into thinking that the effected arm is working.
Study: NCT00419237

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GW685698X
Description: GW685698X will be available as dry white powder to be inhaled via DISKUS containing cellobiose octaacetate (COA) blended with lactose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW685698X
Description: GW685698X will be available as dry white powder to be inhaled via DISKUS containing cellobiose octaacetate (COA) blended with lactose.
Study: NCT00805038

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transplant navigator
Description: Navigator will provide help to patients in completing specific steps in transplant process.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Nephrologists and dialysis facilities will provide usual care regarding access to transplantation.
Study: NCT00345514

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Intervention Arm
Description: The arm emphasized individual provider behavior (interactive CME, feedback at the provider, clinic and program levels, expert modeling, academic detailing and opinion leaders)

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Organizational Interventions Arm
Description: Leadership, team building, benchmarking at the clinic and program level
Study: NCT02495090

Intervention type: GENETIC
Group type: OTHER
Intervention: Exome sequencing
Description: Plain DNA sequencing
Study: NCT04756349

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: composite resin restoration
Description: All patients will receive adhesive composite resin restorations. There will be 3 groups (different adhesives): Clearfil SE, Optibond All-in-One and Prime \& Bond Universal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: composite resin restoration
Description: All patients will receive adhesive composite resin restorations. There will be 3 groups (different adhesives): Clearfil SE, Optibond All-in-One and Prime \& Bond Universal.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: composite resin restoration
Description: All patients will receive adhesive composite resin restorations. There will be 3 groups (different adhesives): Clearfil SE, Optibond All-in-One and Prime \& Bond Universal.
Study: NCT02134041

Intervention type: OTHER
Intervention: traumatic brain injury
Description: mild TBI, GCS \>/=13 after traumatic brain injury
Study: NCT01431469

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Cow's milk
Description: Powdered Whole Cow's Milk

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Follow-On Formula
Description: Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
Study: NCT01512108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: 0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral anti-diabetic drug
Description: An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
Study: NCT02402621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fentanyl
Description: fentanyl with antiemetic drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fentanyl
Description: fentanyl with antiemetic drug
Study: NCT00369746

Intervention type: DRUG
Intervention: citalopram
Description: tablets, 60 mg maximum, daily, 12 weeks

Intervention type: DRUG
Intervention: citalopram
Description: tablets, 60 mg maximum, daily, 12 weeks
Study: NCT02224937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00805818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNZ-2566
Description: Solution for intravenous infusion.~20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1, 3, or 6 mg/kg/h for a total of 72 consecutive hours.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride 0.9% Injection
Study: NCT02287662

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vancouver 3M Clinical Pathway
Study: NCT02278224

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group based rumination focused CBT
Description: The RFCBT is a group trans-diagnostic manual based psychotherapy for depression and anxiety. RFCBT focuses on increasing effective behaviour - i.e., not stopping rumination but making it functional. It's grounded within the core principles and techniques of CBT for depression with two adaptations: (1) a functional-analytical perspective using Behavioural Activation (BA) approaches, (2) an explicit focus on shifting processing style via imagery and experiential approaches.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group based CBT
Description: The control group is gold standard group based CBT based on Becks manual for CBT for depression.
Study: NCT00772811

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Flu-Mel
Description: * Fludarabine and Melphalan will be infused intravenously over 30 minutes in D5W 100 mL.~* Melphalan will be administered following the completion of Fludarabine infusion at day -2.
Study: NCT01039428

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HS219
Description: Chewing for 30 min three time a day far after meal

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Chewing for 30 min three times a day far after meal
Study: NCT00628225

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling and Nicotine replacement (CN)
Description: Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. General practitioners were encouraged to advise nicotine replacement.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling, Nicotine replacement and Bupropion (CNB)
Description: Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. The general practitioner was encouraged to advice the patients to use both nicotine replacements and Bupropion-SR.~Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement and Bupropion-SR.
Study: NCT01644981

Intervention type: OTHER
Intervention: blood sampling
Description: blood sampling
Study: NCT04154995

Intervention type: DIAGNOSTIC_TEST
Intervention: Venipuncture
Description: Blood testing at 3, 6 and 12 months

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound Quadriceps Muscles
Description: Ultrasound measurement of quadriceps muscle mass and health
Study: NCT00679380

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling, endoscopy
Description: Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling, endoscopy
Description: Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Blood sampling, endoscopy
Description: Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Blood sampling, endoscopy
Description: Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide MMX® 6 mg
Description: 6 mg/day, 6 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide MMX® 9 mg
Description: 9 mg/day, 9 mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entocort EC® 3 mg
Description: 9 mg/day, 3 mg tablets
Study: NCT02367183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GED-0301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02786797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR(BC) 6 Week Program
Description: The MBSR(BC) is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. It incorporates simple yoga, sitting meditation, body scan, and walking meditation in this program. Classes for this intervention occur on a weekly basis for 2 hours for 6 weeks. The participants will be asked to record their informal/formal practices in a daily diary during the program and from 6 weeks to 6 months after the intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BCES 6 Week Program
Description: The BCES is an education support program. This 6-week program is based on the published NIH program, Support for People with Cancer: Taking Time Education Support Group. In addition the class sessions consist of group discussion of educational materials and homework assignments; and group processes related to sharing supportive care situations. The participants will record their feelings, coping mechanisms, and questions related to survivorship in a daily diary during the program and from 6 weeks to 6 months after the intervention.
Study: NCT05473702

Intervention type: DEVICE
Intervention: Nanowear SimpleSense Wearable monitoring device
Description: The Nanowear SimpleSense is a non-invasive, wearable and portable medical device for evaluation and monitoring of cardiopulmonary condition. It utilizes physiologic and biometric sensors, SAU, and software system with a suite of algorithms to monitor patient. The parameters include: two vectors of ECG, two vectors of impedance cardiography, thoracic impedance, respiration, heart sounds, and actigraphy and postures. The device is comprised of a wearable device made of an elastomeric harness comprising of active and passive Nanosensors, heart sound sensor, connector to electrically connect the sensors to SAU, it comprises of Inertial Measurement Unit, analog front end, processing unit, storage unit, power supply, and a wireless module, and a software system equipped with the suite of algorithms to monitor heart. The signals are recorded by SAU, transferred to the iPhone over Bluetooth, which later transfers the data to a secure website over an internet connection Wi-fi or mobile network.
Study: NCT02285803

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Study: NCT05238402

Intervention type: DRUG
Intervention: Statin
Description: Statin on COVID 19 patienst

Intervention type: DRUG
Intervention: Statin
Description: Statin on COVID 19 patienst
Study: NCT00289965

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselor-administered Brief Motivational Intervention (BMI)
Description: Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol 101 Plus (interactive CD-ROM)
Description: Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AlcoholEdu (Internet-based tutorial)
Description: Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
Study: NCT04390178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 convalescent plasma
Description: Treatment with convalescent plasma (180-200ml) from individuals who have recovered from SARS-CoV-2 infection
Study: NCT02268344

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Grass SD9 Stimulator
Description: Electrical stimulation will be applied to the nerve using the Grass SD9 Stimulator at a frequency of 20Hz, 10-15V, for 60 minutes during the surgery. This will occur after the neck dissection has been completed, and the remainder of the surgery will continue during stimulation. The stimulation will be applied using the Grass SD9 Stimulator and the current will be conducted to the nerve using a sterile wire electrode that will be encircled around the nerve at its most proximally-exposed portion (skull base). The wire will be removed after 60 minutes of stimulation has been applied.
Study: NCT03910023

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care comporting a home-exercise program (UCHE)
Description: The UCHE intervention will correspond to current practice (including the continuation of previous treatments, if applicable) as decided by the attending physician. The patient will also be provided with a practical guide on how to manage back pain (the back book), including a recommended home exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual care comporting a home-exercise program (UCHE)
Description: The UCHE intervention will correspond to current practice (including the continuation of previous treatments, if applicable) as decided by the attending physician. The patient will also be provided with a practical guide on how to manage back pain (the back book), including a recommended home exercise program.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa therapy
Description: the spa-therapy intervention consists of 18 consecutive days of spa-therapy (excepting Sundays), that must occur with 60 days of randomisation. The latter will combine mineral water with physical and hydrotherapeutic treatments, including massages, heat and water exercises.
Study: NCT02352402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03761160

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Health App
Description: mobile health app aims to provide patients who are about to initiate androgen deprivation therapy for prostate cancer with an exercise program and better eating habit

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care per hospital guidelines
Study: NCT02414984

Intervention type: BIOLOGICAL
Intervention: Golimumab
Description: This is an observational study. Participants with rheumatoid arthritis in Colombia will be observed for 24 months.
Study: NCT02221193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional mouth rinsing and site-specific mouth rinsing (crossover)
Description: blinded prospective, descriptive correlational crossover cross-section clinical trial conduct during the month of Ramadan in the lunar Hajri year 1434 AH (10 July 2013-8 August 2013) in Albaha province in Saudi Arabia involving the application of Listerine® Cool Mint® mouth rinse by either the traditional panoral rinsing method or a site-specific disinfection method targeting the subgingival and supragingival plaque and the posterior third of the tongue dorsum while avoiding the remaining locations within the oral cavity
Study: NCT03000140

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: High Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Moderade Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
Study: NCT02554357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exparel block in arthroscopic shoulder surgery
Description: The interscalene block will be performed with ultrasound guidance and nerve stimulation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine block in shoulder surgery
Description: The interscalene block will be performed with ultrasound guidance and nerve stimulation.
Study: NCT02164760

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Novomaix dermal substitute in combination with STSG
Description: Novomaix dermal substitute in combination with STSG
Study: NCT02685085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol ( Prostaglandin E2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol ( Prostaglandin E2)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley's catheter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foley's catheter
Study: NCT04456660

Intervention type: DIAGNOSTIC_TEST
Intervention: Markers of ultrasound
Description: CRL, HR, and other ultrasound measurements.

Intervention type: DIAGNOSTIC_TEST
Intervention: Immunologic factors
Description: Measurement of NK cells subpopulations types in the maternal serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum factors
Description: Measuring the maternal serum concentration of sFlt-1, PLGF, glycodelin-A, and other substances.